Upcoming event

ASCO Annual Meeting 2023

Article of the Month

Treatment of Low-grade Intermediate-risk Nonmuscle-invasive Bladder Cancer With UGN-102 ± Transurethral Resection of Bladder Tumor Compared to Transurethral Resection of Bladder Tumor Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS)

Primary, nonsurgical chemoablation with UGN-102 for the management of low-grade intermediate-risk nonmuscle-invasive bladder cancer offers a potential therapeutic alternative to immediate transurethral resection of bladder tumor monotherapy and warrants further investigation.

ERUS23 webcast

Robotic approach should be always preferred in every case

Watch now

Robotic surgery; no, thanks. The open standard approach is still the way to go

Watch now

EAU Guidelines

EAU Guidelines

Articles

Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)

Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase III CheckMate 274 trial